During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.
Case-Based Roundtable Meetings Spotlight: March 1, 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Marcia S. Brose, MD, PhD, discussed the case of a patient with advanced thyroid cancer who was previously treated with radioactive iodine and has an NTRK fusion alteration.
During a Targeted Oncology™ Case-Based Roundtable™ event, Sikander Ailawadhi, MD, discussed with participants the choice of regimen for a patient with transplant-eligible newly diagnosed multiple myeloma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
5